Skip to main content
. Author manuscript; available in PMC: 2017 Jul 31.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2016 Jan 22;25(4):363–371. doi: 10.1002/pds.3959

Table 1.

Benefit-harm categories

No harms Minor harms Moderate harms
Patients had no adverse events of interest Patients only had the adverse events that are less worrying including incident cataracts, prescription-requiring hypertension, prescription-requiring hyperlipidemia, or prescription-requiring infections Patients had any of the adverse events that are more worrying including incident glaucoma, requiring cataract surgery and requiring glaucoma surgery

With benefits (1) With benefits/No harms (2) With benefits/Minor harms (3) With benefits/Moderate harms
Patients’ visual acuity of the better-seeing eye remained at better than 20/40 or improved to better than 20/40
No benefits (4) No benefits/No harms (5) No benefits/Minor harms (6) No benefits/Moderate harms
Patients’ visual acuity of the better-seeing eye remained at worse than 20/40 or decreased to worse than 20/40

(7) Missing data
Patients died or were loss to follow-up, or their visual acuity was not or could not be measured